We sought to develop a pharmacologically advanced inhibitor of the oncoprotein RET. Vepafestinib potently inhibited on-target mutants that confer resistance to approved RET inhibitors while exerting ...
Pancreatic ductal adenocarcinoma (PDAC) is a therapeutically challenging disease with poor survival rates, owing to late diagnosis and early dissemination. These tumors frequently undergo perineural ...
Here, we describe the ability of LOXO-292 to overcome acquired RET kinase domain mutations preclinically and in two patients with RET-altered cancers, one with acquired gatekeeper mutation resistance ...
Xueqing Hu , Ujjwol Khatri , Tao Shen , and Jie Wu, at University of Oklahoma Health Sciences Center, USA, provides a comprehensive review of the role of the RET (REarranged during Transfection) ...
Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non–Small-Cell Lung Cancer A global, multicenter network of thoracic oncologists ...
While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in adjuvant NSCLC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results